var data={"title":"Edrophonium: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Edrophonium: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6092?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=edrophonium-drug-information\" class=\"drug drug_general\">see &quot;Edrophonium: Drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164242\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Enlon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164243\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Enlon;</li>\n      <li>Tensilon</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058297\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antidote, Neuromuscular Blocking Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Cholinergic Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Diagnostic Agent, Myasthenia Gravis</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44912694\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Usually administered IV; if not possible, IM or SubQ may be used; however, the results are variable and it may take longer for reaction (Kliegman 2015). Atropine should be available at bedside during the testing for the rare case in which severe bradycardia, cardiac arrhythmia, or hypotension develops. Edrophonium is not the ideal agent in neonates due to its brief effects which make objective assessment difficult; there is also an increased incidence of cardiac arrhythmias associated with this drug when given to neonates (Kliegman 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnosis of myasthenia gravis:</b> Limited data available: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Test dose:</i> Some experts suggest an initial test dose to assess for hypersensitivity or sensitivity to muscarinic effects: IV: 0.01 mg/kg (Kliegman 2015; Swainman 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Diagnostic dose: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 0.1 mg/kg (Avery 1994; Papazian 1992)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\"> IM, SubQ: 0.15 mg/kg, may repeat at doses of 0.15 mg/kg. Maximum total dose: 0.6 mg (Papazian 1992; Schara 2012)  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058292\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=edrophonium-drug-information\" class=\"drug drug_general\">see &quot;Edrophonium: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnosis of myasthenia gravis: Note:</b> Usually administered IV; if not possible, IM or SubQ may be used; however, the results are variable and it may take longer for reaction (Kliegman 2015). Atropine should be available at bedside during the testing for the rare case in which severe bradycardia, cardiac arrhythmia, or hypotension develops.  </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Test dose:</i> Limited data available: Some experts suggest an initial test dose to assess for hypersensitivity or sensitivity to muscarinic effects: IV: 0.01 mg/kg (Kliegman 2015; Swainman 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Diagnostic dose:</i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants: IV: 0.5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&le;34 kg: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">IV: 1 mg; if no response after 45 seconds, it may be repeated in 1 mg increments every 30 to 45 seconds to a total of 5 mg </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">IM: 2 mg </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">&gt;34 kg:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">IV: 2 mg; if no response after 45 seconds, it may be repeated in 1 mg increments every 30 to 45 seconds to a total of 10 mg </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">IM: 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate dosing: Weight-directed dosing: Limited data available: Children and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">IV, IM, SubQ:  Initial: 0.01 to 0.02 mg/kg every 30 to 45 seconds up to the maximum dose (Kliegman 2015; Swaiman 2012). <b>Note:</b> Typical cumulative dose for a 3 to 5 year old is 5 mg/dose (Kliegman 2011) </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum total dose (Kliegman 2015; Swaiman 2012): </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents:  &lt;30 kg:  0.1 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children and Adolescents &ge;30 kg:  0.2 mg/kg or 10 mg; whichever is less</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reversal of nondepolarizing neuromuscular blocking agents:</b> Limited data available: Infants, Children, and Adolescents:  IV:  Usual dose: 0.5 to 1 mg/kg/dose; minimum dose: 0.3 mg/kg/dose (Cote 2013); doses studied range from 0.1 mg/kg to 1.43 mg/kg/dose (Bevan 1996; Fisher 1984; Kirkegaard-Nielsen 1995; Meakin 1983; Abdulatif 1996)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Diagnosis of myasthenia gravis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IV: 2 mg test dose administered over 15 to 30 seconds; if no cholinergic reaction occurs after 45 seconds then administer 8 mg.  If cholinergic reaction occurs after initial test dose, stop testing; test dose may be repeated after 30 minutes.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IM: 10 mg; if cholinergic reaction occurs, give 2 mg 30 minutes later to rule out false-negative reaction </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Evaluation of treatment requirements in myasthenia gravis:</b> IV: 1 to 2 mg given 1 hour after oral dose of anticholinesterase; response will be myasthenic in undertreated patients, adequate in the controlled patient, and cholinergic in the overtreated patient; adjust as appropriate. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Differentiation of cholinergic from myasthenic crisis:</b> IV: 1 mg; may repeat after 1 minute. <b>Note:</b> Intubation and controlled ventilation may be required if patient has cholinergic crisis. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Reversal of nondepolarizing neuromuscular blocking agents:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Manufacturer's labeling: IV: 10 mg over 30 to 45 seconds; may repeat every 5 to 10 minutes up to 40 mg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Alternate recommendations: IV: Usual dose: 0.5 to 1 mg/kg (Engbaek 1985; Miller 2010; Morgan 2013)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>Note:</b> Although the onset of action of neostigmine is delayed, the use of neostigmine with glycopyrrolate is usually preferred due to a longer duration of action. Atropine should be administered along with edrophonium (or glycopyrrolate administered several minutes prior to edrophonium) when reversing the effects of nondepolarizing neuromuscular blocking agents to diminish the cholinergic effects, especially bradycardia (Barash 2009; Morgan 2013). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164225\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Injection, as chloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Enlon: 10 mg/mL (15 mL) [contains phenol]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164211\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058301\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: Edrophonium is administered by direct IV or IM injection; if not possible, SubQ may be used.  </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Diagnosis of myasthenia gravis: Adults: Administer as IV Push over 15 to 30 seconds and follow with a saline flush (Pascuzzi 2003)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45638839\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058300\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Differential diagnosis of myasthenia gravis (FDA approved in pediatric patients [age not specified] and adults); evaluation of treatment in myasthenia gravis (FDA approved in adults); evaluating emergency treatment in myasthenic crises (FDA approved in adults); reversal of nondepolarizing neuromuscular blockers (FDA approved in adults) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164266\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Some reactions listed are based on reports for other agents in this same pharmacologic class and may not be specifically reported for edrophonium.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Cardiovascular: Atrioventricular block, cardiac arrhythmia (especially bradycardia), cardiac arrest, ECG changes (nonspecific), flushing, hypotension, syncope, tachycardia, thrombophlebitis (IV)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Convulsions, dizziness, drowsiness, dysarthria, headache, loss of consciousness, voice disorder</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Diaphoresis, skin rash, urticaria </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea, dysphagia, flatulence, hypersecretory conditions (gastric and intestinal), increased peristalsis, nausea, salivation, stomach cramps, vomiting </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Genitourinary: Urinary frequency, urinary urgency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Fasciculations, laryngospasm, weakness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Conjunctival hyperemia, diplopia, lacrimation, miosis, accommodation disturbance (spasm)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Respiratory: Bronchoconstriction, increased bronchial secretions, respiratory arrest, respiratory paralysis </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164231\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to edrophonium, sulfites, or any component of the formulation; GI or GU obstruction</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164215\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cholinergic crisis: Overdosage can cause cholinergic crisis, which may be fatal.  Atropine should always be readily available as an antagonist and for treatment of cholinergic reactions. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Arrhythmias: Use with caution in patients with cardiac arrhythmias (eg, bradyarrhythmias) due to cholinergic effects.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Asthma: Use with caution in patients with bronchial asthma due to potential bronchoconstriction and/or increased secretions.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myasthenia gravis:  Avoid use as an agent to reverse non-depolarizing neuromuscular blockade in patients with myasthenia gravis; may exacerbate muscular weakness.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug/drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult Drug Interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Sodium sulfite: Products may contain sodium sulfite.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F44912693\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Edrophonium is not recommended for use in infants; its effect is too brief for objective assessment and may have an increased risk of acute cardiac arrhythmias in infants, especially neonates (Kliegman 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299253\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164219\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13266&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Amifampridine: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Amifampridine. Amifampridine side effects may also be increased. Amifampridine may enhance the therapeutic effect of Acetylcholinesterase Inhibitors. Acetylcholinesterase inhibitor side effects may also be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: Acetylcholinesterase Inhibitors may diminish the therapeutic effect of Anticholinergic Agents. Anticholinergic Agents may diminish the therapeutic effect of Acetylcholinesterase Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benoxinate: Acetylcholinesterase Inhibitors may enhance the therapeutic effect of Benoxinate. Specifically, the effects of benoxinate may be prolonged. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Beta-Blockers: Acetylcholinesterase Inhibitors may enhance the bradycardic effect of Beta-Blockers. <b> Exceptions: </b>Levobunolol; Metipranolol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Edrophonium may enhance the AV-blocking effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholinergic Agonists: Acetylcholinesterase Inhibitors may enhance the adverse/toxic effect of Cholinergic Agonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the adverse/toxic effect of Acetylcholinesterase Inhibitors. Increased muscular weakness may occur.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyridamole: May diminish the therapeutic effect of Acetylcholinesterase Inhibitors.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular-Blocking Agents (Nondepolarizing): Acetylcholinesterase Inhibitors may diminish the neuromuscular-blocking effect of Neuromuscular-Blocking Agents (Nondepolarizing). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Succinylcholine: Acetylcholinesterase Inhibitors may increase the serum concentration of Succinylcholine.  Management: Consider alternatives to this combination due to a risk of prolonged neuromuscular blockade.<i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21024362\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Due to the theoretical potential for complications, consider a lower initial dose when using edrophonium for the diagnosis of myasthenia gravis during pregnancy (Varner, 2013).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1058296\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Pre- and postinjection strength (cranial musculature is most useful); heart rate, respiratory rate, blood pressure, changes in fasciculations</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164214\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Inhibits destruction of acetylcholine by acetylcholinesterase. This facilitates transmission of impulses across myoneural junction and results in increased cholinergic responses such as miosis, increased tonus of intestinal and skeletal muscles, bronchial and ureteral constriction, bradycardia, and increased salivary and sweat gland secretions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F164230\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: IM: 2 to 10 minutes; IV: 30 to 60 seconds</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Duration: IM: 5 to 30 minutes: IV: 10 minutes </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: Infants: 1.18 &plusmn; 0.2 L/kg; Children: 1.22 &plusmn; 0.74 L/kg; Adults: 0.9 &plusmn; 0.13 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Infants: 73 &plusmn; 30 minutes; Children: 99 &plusmn; 31 minutes; Adults: 126 &plusmn; 59 minutes; Anephric patients: 2.4 to 4.4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Adults: Primarily urine (67%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Clearance: Infants: 17.8 mL/kg/minute; Children: 14.2 mL/kg/minute; Adults: 8.3 &plusmn; 2.9 mL/kg/minute</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323126\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Enlon Injection)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/mL (15 mL): $96.00</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038609\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Anticude (ES, GR);</li>\n      <li>Camsilon (GB);</li>\n      <li>Enlon (SG);</li>\n      <li>Tensilon (SG)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abdulatif M, Al-Ghamdi A, Al-Sanabary M, Abdel-Gaffar ME. Edrophonium antagonism of intense mivacurium-induced neuromuscular block in children. <i>Br J Anaesth</i>. 1996;76(2):239-244.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edrophonium-pediatric-drug-information/abstract-text/8777104 /pubmed\" target=\"_blank\" id=\"8777104 \">8777104 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Avery, GB, Fletcher, MA, MacDonald MG, eds. Neonatology: Pathophysiology and Management of the Newborn. 4th ed. Philadelphia, PA: J. B. Lippincott Company; 1994.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bevan DR, Kahwaji R, Ansermino JM, Reimer E, Smith MF, O'Connor GA, Bevan JC. Residual block after mivacurium with or without edrophonium reversal in adults and children. <i>Anesthesiology</i>. 1996;84(2):362-367.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edrophonium-pediatric-drug-information/abstract-text/8602667 /pubmed\" target=\"_blank\" id=\"8602667 \">8602667 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cot&eacute; CJ, Lerman J, Anderson BJ, eds. <i>A Practice of Anesthesia Children</i>. 5th ed. Philadelphia, PA: Elsevier Saunders; 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Enlon (edrophonium) [prescribing information]. Rockford, IL: Mylan Institutional LLC; January 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fisher DM, Cronnelly R, Sharma M, Miller RD. Clinical pharmacology of edrophonium in infants and children. <i>Anesthesiology</i>. 1984;61(4):428-433.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edrophonium-pediatric-drug-information/abstract-text/6486504 /pubmed\" target=\"_blank\" id=\"6486504 \">6486504 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kirkegaard-Nielsen H, Meretoja OA, Wirtavuori K. Reversal of atracurium-induced neuromuscular block in paediatric patients. <i>Acta Anaesthesiol Scand</i>. 1995;39(7):906-911.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edrophonium-pediatric-drug-information/abstract-text/8848890 /pubmed\" target=\"_blank\" id=\"8848890 \">8848890 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson' s Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BF, St. Gemell JW, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 19th ed. Philadelphia, PA: Saunders Elsevier; 2011.  </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Meakin G, Sweet PT, Bevan JC, Bevan DR. Neostigmine and edrophonium as antagonists of pancuronium in infants and children. <i>Anesthesiology</i>. 1983;59(4):316-321.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edrophonium-pediatric-drug-information/abstract-text/6311057 /pubmed\" target=\"_blank\" id=\"6311057 \">6311057 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Papazian O. Transient neonatal myasthenia gravis. <i>J Child Neurol</i>. 1992;7(2):135-141. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edrophonium-pediatric-drug-information/abstract-text/1573230 /pubmed\" target=\"_blank\" id=\"1573230 \">1573230 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pascuzzi RM. The edrophonium test. <i>Semin Neurol</i>. 2003;23(1):83-88. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edrophonium-pediatric-drug-information/abstract-text/12870109 /pubmed\" target=\"_blank\" id=\"12870109 \">12870109 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schara U, Della Marina A, Abicht A. Congenital myasthenic syndromes: current diagnostic and therapeutic approaches. <i>Neuropediatrics</i>. 2012;43(4):184-193. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edrophonium-pediatric-drug-information/abstract-text/22911480 /pubmed\" target=\"_blank\" id=\"22911480 \">22911480 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Swaiman KF, Ashwal S, Ferriero DM, Schor NF, eds. Swaiman's Pediatric Neurology: Principles and Practice. 5th ed. Philadelphia, PA: Elsevier Saunders; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tensilon (edrophonium) [prescribing information]. Montreal, Quebec: Valeant Canada Limited; June 2005.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Varner M. Myasthenia gravis and pregnancy. <i>Clin Obstet Gynecol</i>. 2013;56(2):372-381. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/edrophonium-pediatric-drug-information/abstract-text/23563874 /pubmed\" target=\"_blank\" id=\"23563874 \">23563874 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13266 Version 89.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F164242\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F164243\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1058297\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F44912694\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1058292\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F164225\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F164211\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1058301\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F45638839\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1058300\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F164266\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F164231\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F164215\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F44912693\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299253\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F164219\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F21024362\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1058296\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F164214\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F164230\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323126\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038609\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13266|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=edrophonium-drug-information\" class=\"drug drug_general\">Edrophonium: Drug information</a></li></ul></div></div>","javascript":null}